AI Article Synopsis
- The study presents new evidence that small-molecule CCR4 antagonists could be an effective treatment option for CCR4+ CTCL cells.
- These antagonists work by inhibiting the function of CCR4 rather than completely destroying the cells, which could lead to fewer side effects.
- This alternative therapeutic strategy may improve treatment outcomes while reducing the adverse effects typically associated with more aggressive treatments.
Article Abstract
Our findings are of interest to readers because they bring new evidence that small-molecule CCR4 antagonists may be an alternative therapeutic strategy to target CCR4+ CTCL cells. They may inhibit CCR4 function but not eradicate cells, so the side effects may be avoided or minimized.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11494885 | PMC |
| http://dx.doi.org/10.1158/2767-9764.CRC-24-0297 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Small-Molecule CCR4 Antagonists in Cutaneous T-cell Lymphoma.
Cancer Res Commun
October 2024
Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Article Synopsis
- The study presents new evidence that small-molecule CCR4 antagonists could be an effective treatment option for CCR4+ CTCL cells.
- These antagonists work by inhibiting the function of CCR4 rather than completely destroying the cells, which could lead to fewer side effects.
- This alternative therapeutic strategy may improve treatment outcomes while reducing the adverse effects typically associated with more aggressive treatments.
Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 study.
Allergy
April 2024
Laboratory of Inflammatory Skin Diseases, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Background: RPT193 is an orally administered small molecule antagonist of the human C-C motif chemokine receptor 4 (CCR4) that inhibits the migration and downstream activation of T-helper Type 2 (Th2) cells. We investigated single- and multiple-ascending doses of RPT193 in healthy subjects, and multiple doses of RPT193 in subjects with moderate-to-severe atopic dermatitis (AD).
Methods: This was a first-in-human randomized, placebo-controlled Phase 1a/1b monotherapy study (NCT04271514) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and CCR4 surface receptor occupancy in eligible healthy subjects and subjects with moderate-to-severe AD.
ROCK1/MLC2 inhibition induces decay of viral mRNA in BPXV infected cells.
Sci Rep
October 2022
National Centre for Veterinary Type Cultures, ICAR-National Research Centre on Equines, Hisar, India.
Rho-associated coiled-coil containing protein kinase 1 (ROCK1) intracellular cell signaling pathway regulates cell morphology, polarity, and cytoskeletal remodeling. We observed the activation of ROCK1/myosin light chain (MLC2) signaling pathway in buffalopox virus (BPXV) infected Vero cells. ROCK1 depletion by siRNA and specific small molecule chemical inhibitors (Thiazovivin and Y27632) resulted in a reduced BPXV replication, as evidenced by reductions in viral mRNA/protein synthesis, genome copy numbers and progeny virus particles.
View Article and Find Full Text PDFDistepharinamide, a novel dimeric proaporphine alkaloid from Diploclisia glaucescens, inhibits the differentiation and proliferative expansion of CD4Foxp3 regulatory T cells.
Phytomedicine
December 2022
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Science, University of Macau, Macau 999078, China. Electronic address:
Background: CD4Foxp3 regulatory T cells (Tregs) represent the primary cellular mechanism of tumor immune evasion. Elimination of Treg activity by the pharmacological agent may enhance anti-tumor immune responses. However, Treg-eliminating agents, especially those with small molecules, are rarely reported.
View Article and Find Full Text PDFDeadenylase-dependent mRNA decay of GDF15 and FGF21 orchestrates food intake and energy expenditure.
Cell Metab
April 2022
Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA; Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. Electronic address:
Hepatokines, secretory proteins from the liver, mediate inter-organ communication to maintain a metabolic balance between food intake and energy expenditure. However, molecular mechanisms by which hepatokine levels are rapidly adjusted following stimuli are largely unknown. Here, we unravel how CNOT6L deadenylase switches off hepatokine expression after responding to stimuli (e.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!